2:07 PM
 | 
May 16, 2018
 |  BC Extra  |  Clinical News

Endocyte's radioligand therapy reduces PSA in CRPC patients

Newly released data showed that 177Lu-PSMA-617 from Endocyte Inc. (NASDAQ:ECYT) reduced prostate-specific antigen (PSA; KLK3) levels in a Phase II trial to treat metastatic castration-resistant prostate cancer. The data were released in an abstract ahead of the American Society of...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >